LIVER CONDITION IN PATIENTS WITH ACQUIRED VALVULAR DEFECTS OF RHEUMATIC ORIGIN

Komarytsya O. J., Radchenko O. M., Yatsev Yu. M.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Abstract. Valvular heart defects are a significant problem, but little is known about their features in metabolicassociated liver disease and its initial stage - liver steatosis. Objective: to assess the prevalence of liver steatosis in patients with rheumatic valvular defects treated surgically, and to estimate key differences in the structural and functional parameters of heart in its presence. Material and methods: 44 inpatients with chronic rheumatic heart disease who underwent surgical correction of the defect (16 men, 42 women, mean age 54.00±3.69 years) were examined. Diagnostic process was held in accordance with available regulations; standart clinical, laboratory and instrumental data were analyzed; the results were processed by the methods of variation statistics; level of significance was taken as р < 0,05. Results. Patients with chronic rheumatic heart disease with valvular defects were overweight (mean body mass index 29.1 kg/m2 ); 73% of them were diagnosed with liver steatosis, which has unfavourable influence into treatment result according literature data. Liver steatosis in patients with chronic rheumatic heart disease is associated with the activation of inflammatory syndrome according to general fibrinogen increase, impaired carbohydrate metabolism with hyperglycemia, right ventricle dilatation and myocardial hypertrophy (all p < 0.05). According to the conducted correlation analysis, the deterioration of liver condition with impaired function will be accompanied by worsening of structural and functional characteristics of heart, the tendency to the increased thrombosis and lipid and carbohydrate metabolic disorders together with activation of systemic inflammation. Conclusions. The liver steatosis affects the structural and functional parameters of heart, lipid and carbohydrate metabolism, thrombosis, systemic inflammatory activity, so it should be considered in the management of such patients.

liver steatosis, chronic rheumatic heart disease, acquired heart defects, structural and functional parameters of heart, total fibrinogen, blood glucose.

1. Rezzoug N, Vae В, de Meester C, Degryse J, Van Pottelbergh G, Mathei C, et al. The clinical impact of valvular heart disease in a population-based cohort of subjects aged 80 and older. BMC Cardiovascular Disorders. 2016;16:7. doi: 10.1186/s12872-016-0184-8.
2. Lin HXJ, Aravamudan VM. Metabolic associated fatty liver disease and COVID-19: a double whammy?. Singapore Medical J. 2020;PMID:33047142. DOI: 10.11622/smedj.2020141.
3. Shah AM, Ogbara J, Herrmann HC, Fox Z, Kadakia M, Anwaruddin S, et al. Outcomes of transcatheter aortic valve replacement in patients with chronic liver disease. Catheterization & Cardiovascular Interventions. 2015;86(5):888-94. doi: 10.1002/ccd.25994.
4. Ndunda P, Srinivasan S, Vindhyal M, Muutu T, Vukas R, Fanari Z, et al. Clinical Outcomes of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Chronic Liver Disease: A Systematic Review and Metaanalysis. Ochsner J. 2019;19(3):241-247. doi: 10.31486/toj.18.0178.
5. Mari A, Khoury T, Said Ahmad H, Abu Baker F, Kadah A, Sbeit W, et al. The association between non-alcoholic fatty liver disease and valvular heart disease. Minerva Cardioangiologica. 2020;68(1):42-46. doi: 10.23736/S0026-4725.19.05087-4.
6. Ferrara D, Montecucco F, Dallegri F, Carbone F. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. Journal Cell. Physiol. 2019;234(12):21630-21641. doi: 10.1002/jcp.28821.
7. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS.Stahl EP, et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. Journal Am Coll Cardiology. 2019;73(8):948-963. doi: 10.1016/j.jacc.2018.11.050.
8. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544-60. doi: 10.3390/ nu5051544.
9. Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int. J. Environ. Res. Public Health. 2019;16(17):3104-19. doi: 10.3390/ijerph 16173104

«Bulletin of problems biology and medicine» Issue 1 (159), 2021 year, 87-90 pages, index UDK 616.36:616.126.32

10.29254/2077-4214-2021-1-159-87-90